Published in Mov Disord on September 15, 2008
Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation (2009) 1.50
Synergistic effect of norepinephrine transporter blockade and α-2 antagonism on blood pressure in autonomic failure. Hypertension (2012) 1.09
Olfactory dysfunction in pure autonomic failure: Implications for the pathogenesis of Lewy body diseases. Parkinsonism Relat Disord (2009) 1.08
Cardiac sympathetic neuroimaging: summary of the First International Symposium. Clin Auton Res (2009) 1.06
Neuronal source of plasma dopamine. Clin Chem (2008) 0.97
Concepts of scientific integrative medicine applied to the physiology and pathophysiology of catecholamine systems. Compr Physiol (2013) 0.88
Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa. Vasc Health Risk Manag (2014) 0.87
Temporal prolongation of decreased skin blood flow causes cold limbs in Parkinson's disease. J Neural Transm (Vienna) (2012) 0.84
Catecholamines 101. Clin Auton Res (2010) 0.84
Stress, allostatic load, catecholamines, and other neurotransmitters in neurodegenerative diseases. Cell Mol Neurobiol (2012) 0.81
Cardiac sympathetic denervation in 6-OHDA-treated nonhuman primates. PLoS One (2014) 0.81
Hypertension increases cerebral 6-18F-fluorodopa-derived radioactivity. J Nucl Med (2009) 0.79
Neurocardiology: therapeutic implications for cardiovascular disease. Cardiovasc Ther (2010) 0.77
Treatment of dysautonomia in extrapyramidal disorders. Ther Adv Neurol Disord (2010) 0.75
Management of Supine Hypertension Complicating Neurogenic Orthostatic Hypotension. CNS Drugs (2017) 0.75
Sympathetic cardioneuropathy in dysautonomias. N Engl J Med (1997) 3.14
Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med (2000) 2.97
Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl (1994) 2.13
Human ageing and the sympathoadrenal system. J Physiol (2000) 1.93
Vascular adrenergic responsiveness is inversely related to tonic activity of sympathetic vasoconstrictor nerves in humans. J Physiol (2006) 1.79
The distribution of Lewy bodies in pure autonomic failure: autopsy findings and review of the literature. Acta Neuropathol (1997) 1.70
Neurovascular dissociation with paradoxical forearm vasodilation during systemic tyramine administration. Circulation (2003) 1.68
Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology (2002) 1.61
Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma. J Hypertens (2007) 1.61
Pharmacologic distinction of different orthostatic hypotension syndromes. Neurology (1981) 1.59
Orthostatic hypotension as an early finding in Parkinson's disease. Clin Auton Res (2006) 1.52
Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol (2005) 1.51
Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy. Acta Neuropathol (2006) 1.47
PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. J Nucl Med (2006) 1.47
Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol (1997) 1.47
Noninvasive detection of sympathetic neurocirculatory failure. Clin Auton Res (2000) 1.45
Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy. J Neurol Neurosurg Psychiatry (2002) 1.34
Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment. Hypertension (2005) 1.31
Central dopamine deficiency in pure autonomic failure. Clin Auton Res (2008) 1.29
Autonomic failure in neurodegenerative disorders. Semin Neurol (2003) 1.27
Plasma levels of catechols and metanephrines in neurogenic orthostatic hypotension. Neurology (2003) 1.26
Aging effects on human sympathetic neuronal function. Am J Physiol (1995) 1.25
Yohimbine increases sympathetic nerve activity and norepinephrine spillover in normal volunteers. Am J Physiol (1991) 1.23
Dysautonomia in Parkinsonism: a clinicopathological study. J Neurol Neurosurg Psychiatry (1976) 1.21
Adrenergic supersensitivity in parkinsonians with orthostatic hypotension. Eur J Clin Invest (1990) 1.18
Comparison of techniques for measuring baroreflex sensitivity in man. Circulation (1982) 1.16
Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. taki@med.kanazawa-u.ac.jp. Eur J Nucl Med (2000) 1.12
Neuropharmacologic distinction of neurogenic orthostatic hypotension syndromes. Clin Neuropharmacol (2006) 1.03
Patterns of plasma levels of catechols in neurogenic orthostatic hypotension. Ann Neurol (1989) 1.01
Cardiac and extracardiac sympathetic denervation in Parkinson's disease with orthostatic hypotension and in pure autonomic failure. J Nucl Med (2005) 0.99
Different histopathology accounting for a decrease in myocardial MIBG uptake in PD and MSA. Neurology (2001) 0.96
Effects of tyramine on blood pressure and plasma catecholamines in normal and hypertensive subjects. Klin Wochenschr (1982) 0.93
Plasma catecholamine and hemodynamic responses during isoproterenol infusions in humans. Clin Pharmacol Ther (1986) 0.92
A scintigraphical qualitative analysis of peripheral vascular sympathetic function with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst (1995) 0.88
Tyramine-induced vasodilation mediated by dopamine contamination: a paradox resolved. Hypertension (2005) 0.87
Metaiodobenzylguanidine (MIBG) uptake in Parkinson's disease also decreases at thyroid. Ann Nucl Med (2005) 0.86
Neurotransmitter specificity of sympathetic denervation in Parkinson's disease. Neurology (2003) 0.84
Pressor response to intravenous tyramine is a marker of cardiac, but not vascular, adrenergic function. J Cardiovasc Pharmacol (2003) 0.84
Hemodynamic effects of edrophonium chloride (Tensilon) infusion. Chest (1975) 0.83
Evidence for a physiological role of presynaptic alpha-adrenoceptors: modulation of noradrenaline release in the pithed rabbit. Naunyn Schmiedebergs Arch Pharmacol (1983) 0.82
Glucagon does not affect catecholamine release in primary cultures of bovine adrenal chromaffin cells. Horm Metab Res (2005) 0.80
Local sympathetic function in human skeletal muscle and adipose tissue assessed by microdialysis. Clin Auton Res (2002) 0.78
Cardiac beta-adrenoceptor sensitivity and Parkinson's disease. Fundam Clin Pharmacol (1991) 0.77
Takotsubo cardiomyopathy: a new form of acute, reversible heart failure. Circulation (2008) 6.08
Biochemical diagnosis of pheochromocytoma: which test is best? JAMA (2002) 4.84
Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res (2011) 3.88
Neonatal diagnosis and treatment of Menkes disease. N Engl J Med (2008) 2.44
Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev (2004) 2.42
Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer (2004) 2.20
Pandysautonomia associated with impaired ganglionic neurotransmission and circulating antibody to the neuronal nicotinic receptor. Clin Auton Res (2002) 2.18
Supine low-frequency power of heart rate variability reflects baroreflex function, not cardiac sympathetic innervation. Heart Rhythm (2007) 2.01
Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci (2011) 1.82
Carvedilol reverses hyperthermia and attenuates rhabdomyolysis induced by 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) in an animal model. Crit Care Med (2005) 1.76
Association of anosmia with autonomic failure in Parkinson disease. Neurology (2010) 1.72
Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab (2003) 1.70
Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev (2004) 1.69
Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension (2003) 1.69
Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clin Auton Res (2004) 1.66
Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma. J Hypertens (2007) 1.61
Subcutaneous adipose tissue zinc-α2-glycoprotein is associated with adipose tissue and whole-body insulin sensitivity. Obesity (Silver Spring) (2014) 1.56
Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab (2005) 1.55
Baroreflex failure as a late sequela of neck irradiation. Hypertension (2003) 1.54
Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem (2005) 1.52
Low frequency power of heart rate variability reflects baroreflex function, not cardiac sympathetic innervation. Clin Auton Res (2011) 1.50
Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord (2008) 1.49
Failure of propranolol to prevent tilt-evoked systemic vasodilatation, adrenaline release and neurocardiogenic syncope. Clin Sci (Lond) (2006) 1.47
Increased myocardial perfusion and sympathoadrenal activation during mild core hypothermia in awake humans. Clin Sci (Lond) (2003) 1.44
Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies. J Physiol (2013) 1.42
Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease. J Neurochem (2013) 1.34
Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment. Hypertension (2005) 1.31
Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation (2003) 1.30
Phosphorylated α-synuclein in Parkinson's disease. Sci Transl Med (2012) 1.29
Central dopamine deficiency in pure autonomic failure. Clin Auton Res (2008) 1.29
Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis. Neurobiol Dis (2011) 1.29
Cardiac implications of increased arterial entry and reversible 24-h central and peripheral norepinephrine levels in melancholia. Proc Natl Acad Sci U S A (2005) 1.24
Exaggerated adrenomedullary response to immobilization in mice with targeted disruption of the serotonin transporter gene. Endocrinology (2002) 1.23
Differences in ATP7A gene expression underlie intrafamilial variability in Menkes disease/occipital horn syndrome. J Med Genet (2007) 1.23
Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease. PLoS One (2012) 1.23
ATP7A gene addition to the choroid plexus results in long-term rescue of the lethal copper transport defect in a Menkes disease mouse model. Mol Ther (2011) 1.19
Cardiac sympathetic dysautonomia in chronic orthostatic intolerance syndromes. Circulation (2002) 1.18
Prevalence of orthostatic hypotension in Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat Disord (2011) 1.16
Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies. Brain (2012) 1.15
Association of cognitive dysfunction with neurocirculatory abnormalities in early Parkinson disease. Neurology (2012) 1.11
Correction of a rat model of Parkinson's disease by coexpression of tyrosine hydroxylase and aromatic amino acid decarboxylase from a helper virus-free herpes simplex virus type 1 vector. Hum Gene Ther (2003) 1.10
Sympathoneural and adrenomedullary functional effects of alpha2C-adrenoreceptor gene polymorphism in healthy humans. Pharmacogenet Genomics (2005) 1.10
Autoimmune autonomic ganglionopathy: treatment by plasma exchanges and rituximab. Clin Auton Res (2009) 1.08
Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease. J Neurochem (2012) 1.07
Tyrosinase: a developmentally specific major determinant of peripheral dopamine. FASEB J (2003) 1.06
Sympathoadrenal imbalance before neurocardiogenic syncope. Am J Cardiol (2003) 1.05
Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication. Brain (2004) 1.05
Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Am J Pathol (2011) 1.04
Neuropharmacologic distinction of neurogenic orthostatic hypotension syndromes. Clin Neuropharmacol (2006) 1.03
Sympathoneural and adrenomedullary responses to mental stress. Compr Physiol (2015) 1.03
Progressive loss of cardiac sympathetic innervation in Parkinson's disease. Ann Neurol (2002) 1.03
Fish from industrially polluted freshwater as the main source of organochlorinated pollutants and increased frequency of thyroid disorders and dysglycemia. Chemosphere (2007) 1.02
Mechanisms of orthostatic hypotension and supine hypertension in Parkinson disease. J Neurol Sci (2011) 1.02
Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. Eur J Endocrinol (2005) 1.02
Cardiac and extracardiac sympathetic denervation in Parkinson's disease with orthostatic hypotension and in pure autonomic failure. J Nucl Med (2005) 0.99
Protein array reveals differentially expressed proteins in subcutaneous adipose tissue in obesity. Obesity (Silver Spring) (2007) 0.98
Pheochromocytoma: rediscovery as a catecholamine-metabolizing tumor. Endocr Pathol (2003) 0.98
Neuronal source of plasma dopamine. Clin Chem (2008) 0.97
Aging-related changes in cardiac sympathetic function in humans, assessed by 6-18F-fluorodopamine PET scanning. J Nucl Med (2003) 0.97
Heart rate variability and catecholamines during hypoglycemia and orthostasis. Auton Neurosci (2008) 0.96
Multiple adverse thyroid and metabolic health signs in the population from the area heavily polluted by organochlorine cocktail (PCB, DDE, HCB, dioxin). Thyroid Res (2009) 0.94
Neurocirculatory abnormalities in chronic orthostatic intolerance. Circulation (2005) 0.94
Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases. J Clin Invest (2011) 0.93
Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus. Neuropharmacology (2013) 0.93
Leaky catecholamine stores: undue waste or a stress response coping mechanism? Ann N Y Acad Sci (2004) 0.93
Threshold for adrenomedullary activation and increased cardiac work during mild core hypothermia. Clin Sci (Lond) (2002) 0.92
Supine low-frequency power of heart rate variability reflects baroreflex function, not cardiac sympathetic innervation. Cleve Clin J Med (2009) 0.91
Cardiac uptake-1 inhibition by high circulating norepinephrine levels in patients with pheochromocytoma. Hypertension (2004) 0.91
Partial cardiac sympathetic denervation after bilateral thoracic sympathectomy in humans. Heart Rhythm (2005) 0.91
Thyroid ultrasound volume, structure and function after long-term high exposure of large population to polychlorinated biphenyls, pesticides and dioxin. Chemosphere (2007) 0.90